Pediatric Acute Myeloid Leukemia
7
0
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia
Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Home or Away From Home - Descriptive Interviews (Aim 2)
Home Away From Home - Quality of Life Surveys
Optimal Treatment Strategy Based on for Pediatric AML